Federated Hermes Inc. Has $119,000 Stake in InMode Ltd. $INMD

Federated Hermes Inc. reduced its position in InMode Ltd. (NASDAQ:INMD) by 94.7% during the third quarter, Holdings Channel.com reports. The firm owned 8,000 shares of the healthcare company’s stock after selling 144,233 shares during the quarter. Federated Hermes Inc.’s holdings in InMode were worth $119,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Blue Trust Inc. raised its holdings in InMode by 93.7% during the third quarter. Blue Trust Inc. now owns 2,861 shares of the healthcare company’s stock worth $43,000 after buying an additional 1,384 shares during the last quarter. State of Alaska Department of Revenue acquired a new stake in shares of InMode in the 3rd quarter worth about $52,000. Pilgrim Partners Asia Pte Ltd bought a new position in InMode in the 3rd quarter valued at about $69,000. Ritholtz Wealth Management acquired a new position in InMode during the 2nd quarter valued at about $151,000. Finally, Topline Capital Management LLC bought a new stake in InMode during the 2nd quarter worth approximately $160,000. Institutional investors own 68.04% of the company’s stock.

InMode Price Performance

Shares of InMode stock opened at $15.12 on Tuesday. The firm has a market cap of $955.74 million, a PE ratio of 7.00 and a beta of 2.19. InMode Ltd. has a 1 year low of $13.14 and a 1 year high of $19.78. The stock has a fifty day moving average price of $14.66 and a 200-day moving average price of $14.69.

Analysts Set New Price Targets

INMD has been the topic of a number of recent research reports. UBS Group dropped their target price on InMode from $16.25 to $16.00 and set a “neutral” rating on the stock in a report on Thursday, November 6th. BTIG Research restated a “neutral” rating on shares of InMode in a research note on Monday, January 26th. Wall Street Zen downgraded shares of InMode from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Weiss Ratings reiterated a “sell (d+)” rating on shares of InMode in a report on Thursday, January 22nd. Finally, Canaccord Genuity Group set a $15.00 price target on shares of InMode and gave the company a “hold” rating in a research report on Wednesday, December 17th. One research analyst has rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $16.60.

About InMode

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.